Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 21c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. CMG
7. TENB
8. BIIB
9. KLAC
10. ETSY

Go back to Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 21c, Revenues Beat

Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 9, 2020 7:30 AM EST

Positive topline results reported from Study 402, a Phase 3 Study evaluating lumateperone as an adjunctive treatment to lithium or valproate in patients with bipolar depression.

Company is preparing sNDA for the treatment of bipolar depression for submission to the FDA. Study 402, in conjunction with our previously reported positive Phase 3 monotherapy study, Study 404, forms the basis for our sNDA.

Strong CAPLYTA commercial performance with week-over-week and quarter-over-quarter prescription growth despite COVID-19... More